Trial Profile
A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Immunodeficiency disorders
- Focus Proof of concept; Therapeutic Use
- 14 Dec 2020 Status changed from active, no longer recruiting to completed.
- 15 Sep 2020 Planned End Date changed from 20 Jun 2020 to 20 Dec 2020.
- 15 Sep 2020 Planned primary completion date changed from 15 Apr 2020 to 15 Nov 2020.